PRQR

1.71

0.00% 0.00

Dopo l'orario di chiusura: 1.68 -0.03 -1.75%

Proqr Therapeutics N V (PRQR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Forum Previsione

Precedente Chiudi:

$1.71

Aprire:

$1.7

Volume 24 ore:

240.48K

Relative Volume:

0.56

Capitalizzazione di mercato:

$180.17M

Reddito:

$17.91M

Utile/perdita netta:

$-47.66M

Rapporto P/E:

-3.7615

EPS:

-0.4546

Flusso di cassa netto:

$-62.63M

1 W Prestazione:

+14.00%

1M Prestazione:

+8.23%

6M Prestazione:

-24.00%

1 anno Prestazione:

+24.82%

Intervallo 1D:

$1.63

$1.74

Intervallo di 1 settimana:

$1.35

$1.815

Portata 52W:

$1.07

$3.10

Proqr Therapeutics N V Stock (PRQR) Company Profile

Nome

Proqr Therapeutics N V

Settore

Healthcare (1118)

Industria

Biotechnology (624)

Telefono

Indirizzo

Dipendente

187

Cinguettio

@proqr

Prossima data di guadagno

2026-03-12

Ultimi documenti SEC

PRQR's Discussions on Twitter

Compare PRQR vs VRTX, REGN, ARGX, ALNY, INSM

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PRQR Proqr Therapeutics N V	1.71	180.17M	17.91M	-47.66M	-62.63M	-0.4546
VRTX Vertex Pharmaceuticals Inc	438.71	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	761.85	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	746.42	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	318.85	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	162.43	35.01B	606.42M	-1.28B	-997.58M	-6.403

Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-12	Ripresa	Oppenheimer	Outperform
2025-04-29	Ripresa	Cantor Fitzgerald	Overweight
2025-04-29	Iniziato	Evercore ISI	Outperform
2025-03-10	Aggiornamento	Citigroup	Neutral → Buy
2025-01-10	Iniziato	Oppenheimer	Outperform
2024-10-29	Aggiornamento	Raymond James	Outperform → Strong Buy
2023-11-08	Aggiornamento	Chardan Capital Markets	Neutral → Buy
2023-03-30	Aggiornamento	JMP Securities	Mkt Perform → Mkt Outperform
2022-12-22	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2022-02-14	Downgrade	Citigroup	Buy → Neutral
2022-02-11	Downgrade	Raymond James	Strong Buy → Mkt Perform
2022-02-11	Downgrade	Stifel	Buy → Hold
2022-02-01	Iniziato	Raymond James	Strong Buy
2021-05-03	Iniziato	Stifel	Buy
2021-03-25	Reiterato	Citigroup	Buy
2020-11-03	Ripresa	Cantor Fitzgerald	Overweight
2019-03-12	Reiterato	Chardan Capital Markets	Buy
2018-12-19	Iniziato	RBC Capital Mkts	Outperform
2018-11-15	Iniziato	Citigroup	Buy
2018-09-19	Iniziato	Evercore ISI	Outperform
2017-09-26	Reiterato	JMP Securities	Mkt Outperform
2016-06-20	Iniziato	Chardan Capital Markets	Neutral
2014-10-15	Iniziato	Deutsche Bank	Buy
2014-10-13	Iniziato	H.C. Wainwright	Buy

Mostra tutto

Proqr Therapeutics N V Borsa (PRQR) Ultime notizie

Apr 04, 2026

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Apr 01, 2026

What analysts say about ProQR Therapeutics NV stockWeekly Trend Recap & Expert Verified Movement Alerts - baoquankhu1.vn

Apr 01, 2026

Mar 31, 2026

US Market Recap: Can ProQR Therapeutics NV benefit from deglobalization2026 Summary & Detailed Earnings Play Alerts - baoquankhu1.vn

Mar 31, 2026

Mar 30, 2026

Aug Reactions: Can ProQR Therapeutics NV weather a recessionMarket Growth Report & AI Forecasted Entry and Exit Points - baoquankhu1.vn

Mar 30, 2026

Mar 27, 2026

PRQR SEC FilingsProqr Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 27, 2026

Mar 26, 2026

Retail Trends: Will ProQR Therapeutics NV stock recover after earningsIPO Watch & Safe Swing Trade Setup Alerts - baoquankhu1.vn

Mar 26, 2026

ProQR Sets April 8 Virtual Investor Event to Spotlight Axiomer RNA Editing Pipeline - The Globe and Mail

Mar 26, 2026

Price Action: Is ProQR Therapeutics NV attractive for institutional investors2026 Pullback Review & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn

Mar 26, 2026

Mar 25, 2026

Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts - Yahoo Finance

Mar 25, 2026

ProQR (PRQR) schedules April 8 virtual event on Axiomer RNA pipeline - Stock Titan

Mar 25, 2026

ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026 - GlobeNewswire

Mar 25, 2026

Ahead of AX-0810 data, ProQR plans April 8 pipeline webcast - Stock Titan

Mar 25, 2026

Mar 20, 2026

Evercore ISI Group Initiates Coverage of ProQR Therapeutics N.V. (PRQR) with Outperform Recommendation - MSN

Mar 20, 2026

Mar 19, 2026

Research Analysts Set Expectations for PRQR Q2 Earnings - Defense World

Mar 19, 2026

Mar 18, 2026

ProQR (NASDAQ: PRQR) director details substantial share and long-dated option holdings - Stock Titan

Mar 18, 2026

ProQR (PRQR) CSO details sizeable option grants and share stake - Stock Titan

Mar 18, 2026

Director Maier details ProQR (PRQR) share option grants and vesting - Stock Titan

Mar 18, 2026

ProQR (PRQR) director Alison Lawton details multiple option grants - Stock Titan

Mar 18, 2026

ProQR (PRQR) CFO discloses 1,000,000-share option position in Form 3 - Stock Titan

Mar 18, 2026

Theresa Heggie (PRQR) details option and share holdings in Form 3 - Stock Titan

Mar 18, 2026